Do analysts recommend PBM or EVAX?

Evaxion A/S has a consensus price target of $11.00, indicating a potential upside of 260.66%. Given Evaxion A/S's stronger consensus rating and higher possible upside, analysts plainly believe Evaxion A/S is more favorable than Psyence Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evaxion A/S 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is PBM or EVAX more profitable?

Psyence Biomedical's return on equity of 0.00% beat Evaxion A/S's return on equity. Company Net Margins Return on Equity Return on Assets Psyence Biomedical N/A N/A N/A Evaxion A/S N/A -73.56% -37.45%

Does the media prefer PBM or EVAX?

In the previous week, Psyence Biomedical and Psyence Biomedical both had 2 articles in the media. Psyence Biomedical's average media sentiment score of 1.27 beat Evaxion A/S's score of 0.93 indicating that Psyence Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Psyence Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evaxion A/S 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend PBM or MRKR?

Marker Therapeutics has a consensus price target of $10.00, indicating a potential upside of 604.23%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Marker Therapeutics is more favorable than Psyence Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Marker Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has preferable earnings & valuation, PBM or MRKR?

Marker Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Psyence Biomedical N/A N/A -$6.94M $25.34 0.11 Marker Therapeutics N/A N/A -$12.16M -$0.61 N/A

Is BRNS or PBM more profitable?

Psyence Biomedical's return on equity of 0.00% beat Barinthus Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Barinthus Biotherapeutics N/A -63.83% -48.77% Psyence Biomedical N/A N/A N/A

Do analysts recommend PBM or BTAI?

BioXcel Therapeutics has a consensus price target of $11.00, indicating a potential upside of 1,086.62%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than Psyence Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is PBM or BTAI more profitable?

Psyence Biomedical has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. Company Net Margins Return on Equity Return on Assets Psyence Biomedical N/A N/A N/A BioXcel Therapeutics -11,078.53% N/A -201.53%

Does the media favor PBM or BTAI?

In the previous week, Psyence Biomedical and Psyence Biomedical both had 2 articles in the media. Psyence Biomedical's average media sentiment score of 1.27 beat BioXcel Therapeutics' score of 0.85 indicating that Psyence Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Psyence Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioXcel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend PBM or KALA?

KALA BIO has a consensus target price of $1,158.33, suggesting a potential upside of 113,462.09%. Given KALA BIO's stronger consensus rating and higher probable upside, analysts plainly believe KALA BIO is more favorable than Psyence Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 KALA BIO 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, PBM or KALA?

KALA BIO is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Psyence Biomedical N/A N/A -$6.94M $25.34 0.11 KALA BIO N/A N/A -$26.98M -$96.14 N/A

Is PBM or KALA more profitable?

Psyence Biomedical's return on equity of 0.00% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets Psyence Biomedical N/A N/A N/A KALA BIO N/A -1,336.10% -94.85%

Does the media refer more to PBM or KALA?

In the previous week, KALA BIO had 1 more articles in the media than Psyence Biomedical. MarketBeat recorded 3 mentions for KALA BIO and 2 mentions for Psyence Biomedical. Psyence Biomedical's average media sentiment score of 1.27 beat KALA BIO's score of 0.47 indicating that Psyence Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Psyence Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive KALA BIO 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Psyence Biomedical (PBM) Competitors

$2.89 +0.02 (+0.70%)

Closing price 04:00 PM Eastern

Extended Trading

$2.93 +0.04 (+1.35%)

As of 04:39 PM Eastern

Compare

PBM vs. EVAX, MRKR, BRNS, BTAI, and KALA

Should you buy Psyence Biomedical stock or one of its competitors? MarketBeat compares Psyence Biomedical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Psyence Biomedical include Evaxion A/S (EVAX), Marker Therapeutics (MRKR), Barinthus Biotherapeutics (BRNS), BioXcel Therapeutics (BTAI), and KALA BIO (KALA). These companies are all part of the "pharmaceutical products" industry.

How does Psyence Biomedical compare to Evaxion A/S?

Psyence Biomedical (NASDAQ:PBM) and Evaxion A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

77.4% of Psyence Biomedical shares are owned by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Psyence Biomedical's return on equity of 0.00% beat Evaxion A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
Evaxion A/S	N/A	-73.56%	-37.45%

Evaxion A/S has a consensus price target of $11.00, indicating a potential upside of 260.66%. Given Evaxion A/S's stronger consensus rating and higher possible upside, analysts plainly believe Evaxion A/S is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Psyence Biomedical has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

Psyence Biomedical has higher earnings, but lower revenue than Evaxion A/S. Evaxion A/S is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.11
Evaxion A/S	$7.53M	3.38	-$7.71M	-$1.47	N/A

In the previous week, Psyence Biomedical and Psyence Biomedical both had 2 articles in the media. Psyence Biomedical's average media sentiment score of 1.27 beat Evaxion A/S's score of 0.93 indicating that Psyence Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Psyence Biomedical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evaxion A/S	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Psyence Biomedical beats Evaxion A/S on 8 of the 13 factors compared between the two stocks.

How does Psyence Biomedical compare to Marker Therapeutics?

Psyence Biomedical (NASDAQ:PBM) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

In the previous week, Psyence Biomedical and Psyence Biomedical both had 2 articles in the media. Marker Therapeutics' average media sentiment score of 1.44 beat Psyence Biomedical's score of 1.27 indicating that Marker Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Psyence Biomedical	Positive
Marker Therapeutics	Positive

Psyence Biomedical has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

Marker Therapeutics has a consensus price target of $10.00, indicating a potential upside of 604.23%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Marker Therapeutics is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Marker Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.11
Marker Therapeutics	N/A	N/A	-$12.16M	-$0.61	N/A

77.4% of Psyence Biomedical shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 3.6% of Psyence Biomedical shares are held by insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Psyence Biomedical has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Psyence Biomedical's return on equity of 0.00% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
Marker Therapeutics	-343.03%	-73.29%	-59.70%

Summary

Psyence Biomedical beats Marker Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Psyence Biomedical compare to Barinthus Biotherapeutics?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Barinthus Biotherapeutics has a beta of -0.41, indicating that its stock price is 141% less volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market.

25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are owned by institutional investors. 8.5% of Barinthus Biotherapeutics shares are owned by insiders. Comparatively, 3.6% of Psyence Biomedical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Psyence Biomedical has lower revenue, but higher earnings than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.75	-$66.43M	-$1.29	N/A
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.11

In the previous week, Barinthus Biotherapeutics and Barinthus Biotherapeutics both had 2 articles in the media. Psyence Biomedical's average media sentiment score of 1.27 beat Barinthus Biotherapeutics' score of 0.44 indicating that Psyence Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
Barinthus Biotherapeutics	Neutral
Psyence Biomedical	Positive

Barinthus Biotherapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 525.00%. Given Barinthus Biotherapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Barinthus Biotherapeutics is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Psyence Biomedical's return on equity of 0.00% beat Barinthus Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%
Psyence Biomedical	N/A	N/A	N/A

Summary

Psyence Biomedical beats Barinthus Biotherapeutics on 8 of the 13 factors compared between the two stocks.

How does Psyence Biomedical compare to BioXcel Therapeutics?

Psyence Biomedical (NASDAQ:PBM) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

In the previous week, Psyence Biomedical and Psyence Biomedical both had 2 articles in the media. Psyence Biomedical's average media sentiment score of 1.27 beat BioXcel Therapeutics' score of 0.85 indicating that Psyence Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Psyence Biomedical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioXcel Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Psyence Biomedical has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

Psyence Biomedical has higher earnings, but lower revenue than BioXcel Therapeutics. BioXcel Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.11
BioXcel Therapeutics	$640K	44.73	-$69.90M	-$5.75	N/A

Psyence Biomedical has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%

BioXcel Therapeutics has a consensus price target of $11.00, indicating a potential upside of 1,086.62%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

77.4% of Psyence Biomedical shares are held by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are held by institutional investors. 3.6% of Psyence Biomedical shares are held by insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Psyence Biomedical beats BioXcel Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Psyence Biomedical compare to KALA BIO?

Psyence Biomedical (NASDAQ:PBM) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

In the previous week, KALA BIO had 1 more articles in the media than Psyence Biomedical. MarketBeat recorded 3 mentions for KALA BIO and 2 mentions for Psyence Biomedical. Psyence Biomedical's average media sentiment score of 1.27 beat KALA BIO's score of 0.47 indicating that Psyence Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Psyence Biomedical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
KALA BIO	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Psyence Biomedical's return on equity of 0.00% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
KALA BIO	N/A	-1,336.10%	-94.85%

KALA BIO is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.11
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

KALA BIO has a consensus target price of $1,158.33, suggesting a potential upside of 113,462.09%. Given KALA BIO's stronger consensus rating and higher probable upside, analysts plainly believe KALA BIO is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Psyence Biomedical has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.35, meaning that its share price is 335% less volatile than the broader market.

77.4% of Psyence Biomedical shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by insiders. Comparatively, 2.2% of KALA BIO shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Psyence Biomedical beats KALA BIO on 9 of the 13 factors compared between the two stocks.

Get Psyence Biomedical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PBM vs. The Competition

Export

Metric	Psyence Biomedical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.63M	$3.67B	$6.76B	$12.66B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	0.11	21.47	27.10	24.38
Price / Sales	N/A	329.21	525.30	91.65
Price / Cash	N/A	143.66	48.59	59.39
Price / Book	0.39	8.58	10.82	6.32
Net Income	-$6.94M	$23.88M	$3.59B	$331.55M
7 Day Performance	-0.34%	-2.33%	-1.24%	0.08%
1 Month Performance	-12.42%	6.48%	3.11%	-0.74%
1 Year Performance	-91.18%	53.33%	29.11%	20.69%

Psyence Biomedical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PBM Psyence Biomedical	1.3234 of 5 stars	$2.89 +0.7%	N/A	-91.4%	$6.63M	N/A	0.11	N/A	Positive News
EVAX Evaxion A/S	3.1158 of 5 stars	$3.20 -1.5%	$11.00 +243.8%	+13.5%	$26.69M	$7.53M	N/A	60	Gap Up
MRKR Marker Therapeutics	3.2181 of 5 stars	$1.58 -1.9%	$10.00 +532.9%	-8.9%	$26.34M	$3.55M	N/A	60	Short Interest Decrease
BRNS Barinthus Biotherapeutics	2.1479 of 5 stars	$0.64 +0.1%	$4.00 +527.1%	-39.9%	$26.06M	N/A	N/A	107	Short Interest Increase
BTAI BioXcel Therapeutics	2.6899 of 5 stars	$0.84 +4.4%	$11.00 +1,213.0%	-49.0%	$25.87M	$680K	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PBM) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Psyence Biomedical (PBM) Competitors

PBM vs. EVAX, MRKR, BRNS, BTAI, and KALA

How does Psyence Biomedical compare to Evaxion A/S?

Summary

How does Psyence Biomedical compare to Marker Therapeutics?

Summary

How does Psyence Biomedical compare to Barinthus Biotherapeutics?

Summary

How does Psyence Biomedical compare to BioXcel Therapeutics?

Summary

How does Psyence Biomedical compare to KALA BIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBM vs. The Competition

Psyence Biomedical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Psyence Biomedical (PBM) Competitors

PBM vs. EVAX, MRKR, BRNS, BTAI, and KALA

How does Psyence Biomedical compare to Evaxion A/S?

Do institutionals and insiders have more ownership in PBM or EVAX?

Is PBM or EVAX more profitable?

Do analysts recommend PBM or EVAX?

Which has more volatility and risk, PBM or EVAX?

Which has higher earnings and valuation, PBM or EVAX?

Does the media prefer PBM or EVAX?

Summary

How does Psyence Biomedical compare to Marker Therapeutics?

Does the media refer more to PBM or MRKR?

Which has more risk and volatility, PBM or MRKR?

Do analysts recommend PBM or MRKR?

Which has preferable earnings & valuation, PBM or MRKR?

Do institutionals and insiders have more ownership in PBM or MRKR?

Is PBM or MRKR more profitable?

Summary

How does Psyence Biomedical compare to Barinthus Biotherapeutics?

Which has more risk & volatility, BRNS or PBM?

Do insiders and institutionals hold more shares of BRNS or PBM?

Which has preferable valuation & earnings, BRNS or PBM?

Does the media prefer BRNS or PBM?

Do analysts recommend BRNS or PBM?

Is BRNS or PBM more profitable?

Summary

How does Psyence Biomedical compare to BioXcel Therapeutics?

Does the media favor PBM or BTAI?

Which has more risk & volatility, PBM or BTAI?

Which has preferable earnings and valuation, PBM or BTAI?

Is PBM or BTAI more profitable?

Do analysts recommend PBM or BTAI?

Do insiders and institutionals have more ownership in PBM or BTAI?

Summary

How does Psyence Biomedical compare to KALA BIO?

Does the media refer more to PBM or KALA?

Is PBM or KALA more profitable?

Which has better valuation & earnings, PBM or KALA?

Do analysts recommend PBM or KALA?

Which has more risk and volatility, PBM or KALA?

Do insiders & institutionals hold more shares of PBM or KALA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBM vs. The Competition

Psyence Biomedical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools